Navigation Links
Rib-X Pharmaceuticals Announces Presentations at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Date:5/7/2009

NEW HAVEN, Conn., May 7 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery and development of novel antibiotics for the treatment of antibiotic-resistant infections, today announced that researchers will be presenting two presentations and two posters at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) taking place in Helsinki, Finland from May 16-19, 2009.

Independent researchers, Dr. Franciose van Bambeke and Dr. Sandrine Lemaire, both from Universite Catholique de Louvain, will each make oral presentations describing the unique microbiological and pharmacodynamic properties of Rib-X's novel oxazolidinone, radezolid, during a session entitled Pharmacokinetics/Pharmacodynamics: Clinical Relevance, on Saturday, May 16th.

Additionally, Rib-X researchers will be presenting two posters on delafloxacin, one of which discusses the activity and efficacy of delafloxacin in a Phase 2 clinical trial for complicated Skin and Skin Structure Infections. The second poster session details the in vitro activity of delafloxacin against a large, worldwide panel of methicillin-resistant Staphylococcus aureus.

    Details on the presentations and abstracts are as follows:

     Date        Time    Session          Title                Location/Poster

    May 16,    3:06pm -   PK/PD:     The novel oxazolidinone   Lecture Hall 3a
     2009      3:18pm     Clinical   radezolid (RX-1741)
                          Relevance  accumulates in THP-1
                                     macrophages: comparative
                                     studies with linezolid
                                     and azithromycin.

    May 16,    3:18pm -   PK/PD:     Radezolid (RX-1741), a    Lecture Hall 3a
     2009      3:30pm     Clinical   novel oxazolidinone, is
                          Relevance  active against
                                     intracellular S. aureus,
                                     L. monocytogenes and L.
                                     pneumophila phagocytosed
                                     by human THP-1 macrophages.

    May 17,    1:30pm -   Poster     In vitro activity of      Topic 31: New
     2009      2:30pm     Session 3  delafloxacin against      antimicrobials
                                     methicillin-resistant     against Gram-
                                     Staphylococcus aureus     positives
                                     from the United States,   Poster #1080
                                     Europe and Asia.

    May 18,    1:30pm -   Poster     Results of a Phase 2      Topic 71:
     2009      2:30pm     Session 5  Study Comparing Two       Clinical trials
                                     Doses of Delafloxacin to  of antibiotics
                                     Tigecycline in Adults     Poster #1794
                                     with Complicated Skin and
                                     Skin Structure Infections

About Rib-X Pharmaceuticals, Inc.

Rib-X Pharmaceuticals, Inc. is a product-driven small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. NDAs for Rib-X's most advanced compounds, delafloxacin and radezolid, are anticipated in the 2011/2012 timeframe. The Company's underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the ribosome, which performs an essential role in protein synthesis. Many known, commercially valuable antibiotics exert their effects by binding to the bacterial ribosome. The Company's integrated research strategy, which combines state-of-the-art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology and biochemistry, allows it to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded several distinctive new antibiotics that can be used for the treatment of either community- or hospital-acquired infections. The Company has recently completed Phase 2 trials in cSSTI with the IV form of delafloxacin, and is currently in Phase 2 trials with radezolid (RX-1741), an oxazolidinone that was discovered at Rib-X, as an oral/IV agent for treatment of serious Gram-positive infections and community or hospital acquired pneumonias. The RX-04 discovery program is developing novel classes of antibiotics active against multi-drug resistant Gram-negative bacteria and the RX-02 discovery program is focused on developing an IV/oral macrolide active against methicillin-resistant S. aureus, multidrug-resistant Streptococcus pneumoniae and S. pyogenes.

For more information on the Rib-X mission and the pipeline, please visit the Company website at www.rib-x.com.


'/>"/>
SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing
2. Rib-X Pharmaceuticals to Present at the 2008 ICAAC/IDSA Joint Meeting
3. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
4. Rib-X Pharmaceuticals to Present at Cambridge Healthtech Institutes 2nd Annual Challenge of Antibacterial Development Conference
5. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
6. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
7. Savient Pharmaceuticals Reports First Quarter 2009 Financial Results
8. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, May 11, 2009
9. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Two Investment Conferences During the Month of May 2009
10. Amylin Pharmaceuticals Announces a New Sales Approach to Better Target the Diabetes Market
11. First Patient Dosed in Phase I Clinical Trial of Tigris Pharmaceuticals GGTI-2418
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016  Global demand for enzymes is ... 2020 to $7.2 billion.  This market includes enzymes ... products, biofuel production, animal feed, and other markets) ... biocatalysts). Food and beverages will remain the largest ... consumption of products containing enzymes in developing regions.  ...
(Date:6/27/2016)... ... June 27, 2016 , ... Cancer experts ... they believe could be a new and helpful biomarker for malignant pleural mesothelioma. ... here to read it now. , Biomarkers are components in the blood, ...
(Date:6/27/2016)... Hill, N.C. (PRWEB) , ... June 27, 2016 ... ... U.S. commercial operations for Amgen, will join the faculty of the University ... serve as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a ...
(Date:6/24/2016)... , June 24, 2016  Regular discussions on a ... take place between the two entities said Poloz. ... Ottawa , he pointed to the country,s ... the federal government. ... said, "Both institutions have common economic goals, why not sit ...
Breaking Biology Technology:
(Date:5/20/2016)... 20, 2016  VoiceIt is excited to announce ... By working together, VoiceIt and VoicePass ... and VoicePass take slightly different approaches to voice ... security and usability. ... new partnership. "This marketing and technology ...
(Date:4/28/2016)... and BANGALORE, India , April ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... today announced a global partnership that will provide ... to use mobile banking and payment services.      ... a key innovation area for financial services, but it also ...
(Date:4/15/2016)... , April 15, 2016  A new ... make more accurate underwriting decisions in a fraction ... timely, competitively priced and high-value life insurance policies ... screenings. With Force Diagnostics, rapid testing ... lifestyle data readings (blood pressure, weight, pulse, BMI, ...
Breaking Biology News(10 mins):